An influential U.S. federal advisory panel overwhelmingly rejected a plan Friday to offer Pfizer-BioNTech booster shots against COVID-19 to most Americans, dealing a heavy blow to the Biden administration’s effort to shore up people’s protection amid the highly contagious delta variant.

The surprising vote by the committee of outside experts assembled by the U.S. Food and Drug Administration (FDA) was 16-2, with members expressing frustration that Pfizer had provided little data on the safety of extra doses. Many also raised doubts about the value of mass boosters, rather than ones targeted to specific groups.

In an extraordinary move, both FDA leaders and the panel indicated they were likely to take a second vote Friday afternoon on recommending the booster shots for older Americans and other high-risk groups.

That would help salvage part of the White House’s campaign but would still be a huge step back from the sweeping plan proposed a month ago to offer booster shots of both the Pfizer and Moderna vaccines to nearly all Americans eight months after they get their second dose.

Vigorous debate

During several hours of vigorous debate Friday, members of the panel questioned the value of offering boosters to nearly everyone.

“I don’t think a booster dose is going to significantly contribute to controlling the pandemic,” said Dr. Cody Meissner of Tufts University. “And I think it’s important that the main message we transmit is that we’ve got to get everyone two doses.”

Dr. Amanda Cohn of the U.S. Centers for Disease Control and Prevention said: “At this moment it is clear that the unvaccinated are driving transmission in the United States.”

Panel members also complained that data provided by Israeli researchers about their booster campaign might not be suitable for predicting the U.S. experience.

Scientists inside and outside the government have been divided in recent days over the need for boosters and who should get them, and the World Health Organization has strongly objected to rich nations giving a third round of shots when poor countries don’t have enough vaccine for their first.

While research suggests immunity levels in those who have been vaccinated wane over time and boosters can reverse that, the Pfizer vaccine is still highly protective against severe illness and death, even amid the spread of the highly contagious delta variant.

The surprise turn of events could reinforce recent criticism that the Biden administration got out ahead of the science in its push for boosters. U.S. President Joe Biden promised early on that his administration would “follow the science,” following disclosures of political meddling in the Trump administration’s coronavirus response.

The FDA advisory panel was the first major hurdle that the Biden administration plan faced. The FDA itself has yet to make its own determination but typically follows the recommendations of its expert panel.


Scource From CBC News

Leave a Reply

Your email address will not be published. Required fields are marked *

Sign Up for Our Newsletters

Get notified of the fresh news from Montrealecodaily.com

You May Also Like

Giuliani associate Lev Parnas convicted of campaign finance crimes

A Florida businessman who helped Rudy Giuliani’s effort to dig up dirt…

Japan’s Princess Mako marries commoner, loses royal status

Japanese Princess Mako quietly married a commoner without traditional wedding celebrations Tuesday…

China condemns Canada, U.S. for sending warships through Taiwan Strait

The Chinese military on Sunday condemned Canada and the United States for…

Delta Air Lines will soon charge unvaccinated workers $200 a month health premium

Delta Air Lines will charge employees on the company health plan $200…